Maturitas 41 (2002) 51–60
Effect of postmenopausal hormone replacement on
atherosclerosis in femoral arteries
Peter Angerer *, Stefan Sto ¨ rk, Wolfgang Kothny, Clemens von Schacky
Klinikum der Uniersita ¨t Mu ¨nchen, Institut und Poliklinik fu ¨r Arbeits - und Umweltmedizin, Medizinische Klinik -Innenstadt,
Ziemssenstraße 1, 80336 Mu ¨nchen, Germany
Received 26 January 2001; received in revised form 9 July 2001; accepted 16 July 2001
Abstract
Objecties: On the basis of epidemiological and experimental data, it has been supposed that hormone replacement
therapy (HRT) inhibits atherosclerosis in postmenopausal women. This randomized controlled trial examined
whether 1 mg 17-estradiol daily, combined cyclically with 0.025 mg gestodene in every month (HRT 1), or in every
third month (HRT 2) slows the increase of intima-media thickness in femoral arteries compared with no HRT.
Methods: Healthy postmenopausal women (n =321) with an increased risk for future vascular disease as indicated by
1 mm of intima-media thickness in the carotid arteries were equally randomized to one of the three groups for 48
weeks. Ultrasound scans of femoral arteries were recorded at study start and study end, together with a thorough
clinical examination and laboratory work-up. Results: Complete scans were obtained in 260 of the 264 subjects who
participated until study end. Mean maximum intima-media thickness of four femoral artery segments (common and
superficial, both sides) was 0.93 0.37 mm (mean S.D.) at study start. It increased by 0.02 0.05, 0.02 0.05, and
0.03 0.05 mm in the HRT 1, HRT 2 and no HRT groups, respectively (HRT 1 versus no HRT, HRT 2 versus no
HRT; both P 0.2). Compared with no HRT, HRT significantly lowered follicle stimulating hormone, low-density
lipoprotein cholesterol, and fibrinogen. Conclusions: In this 1-year trial, irrespective of the progestogen dose used,
HRT with 1 mg 17-estradiol did not inhibit progression of femoral artery atheroslerosis in postmenopausal women
with subclinical vascular disease. © 2002 Elsevier Science Ireland Ltd. All rights reserved.
Keywords: 17-Estradiol; Hormone replacement therapy; Atherosclerosis; Femoral arteries; Intima-media thickness; Randomized
controlled trial
www.elsevier.com/locate/maturitas
Abbreiations: ABI, ankle/brachial (systolic blood pressure) index; CAD, coronary artery disease; FSH, follicle stimulating
hormone; HDL, high-density lipoprotein cholesterol; HRT, hormone replacement therapy; IMT, intima-media thickness; LDL,
low-density lipoprotein cholesterol; PAD, peripheral arterial disease.
* Corresponding author. Tel.: +49-89-5160-2440; Fax: +49-89-5160-4444.
E-mail address: peter.angerer@arbeits.med.uni-muenchen.de (P. Angerer).
0378-5122/02/$ - see front matter © 2002 Elsevier Science Ireland Ltd. All rights reserved.
PII:S0378-5122(01)00255-9